Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
Go back to Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics| GALMED PHARMACEUTIC (NASDAQ: GLMD) | Delayed: 0.55 -0.01 (1.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.56 | 52 Week High | $9.70 | |||
| Open | $0.53 | 52 Week Low | $2.78 | |||
| Day High | $0.56 | P/E | N/A | |||
| Day Low | $0.53 | EPS | $0.00 | |||
| Volume | 10,489 | |||||
